Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of R484iv by intravenous intermittent administration to
patients with primary osteoporosis in comparison with sodium risedronate hydrate (RIS) by
oral administration every day. To evaluate also the dose response of R484iv.
Phase:
Phase 3
Details
Lead Sponsor:
Chugai Pharmaceutical
Treatments:
Calcium Cholecalciferol Diphosphonates Ibandronic Acid Vitamin D Vitamins